These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 10326149)
21. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]. Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194 [TBL] [Abstract][Full Text] [Related]
22. Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Sherry S Am J Cardiol; 1987 Apr; 59(9):984-9. PubMed ID: 3105303 [No Abstract] [Full Text] [Related]
23. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Wooster MB; Luzier AB Ann Pharmacother; 1999 Mar; 33(3):318-24. PubMed ID: 10200858 [TBL] [Abstract][Full Text] [Related]
24. New thrombolytic drugs. Thomson A Aust N Z J Med; 1999 Jun; 29(3):433-5. PubMed ID: 10868516 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Smalling RW Eur Heart J; 1997 Dec; 18 Suppl F():F11-6. PubMed ID: 9447335 [TBL] [Abstract][Full Text] [Related]
26. [Platelet activation in the early phases of acute myocardial infarction]. Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873 [TBL] [Abstract][Full Text] [Related]
27. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D; Lijnen HR Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451 [TBL] [Abstract][Full Text] [Related]
28. [t-PA in thrombolytic therapy of acute myocardial infarct]. Rutsch W; Schmutzler H Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690 [TBL] [Abstract][Full Text] [Related]
29. Reteplase set to enter thrombolytic market. Am J Health Syst Pharm; 1997 Jan; 54(1):12. PubMed ID: 9117779 [No Abstract] [Full Text] [Related]
30. TIMI grade flow, mortality, and the GUSTO-III trial. Stringer KA Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644 [TBL] [Abstract][Full Text] [Related]
31. Clinical trial results with a new plasminogen activator. Bode C; Peter K; Moser M; Smalling RW; Weaver WD Eur Heart J; 1997 Dec; 18 Suppl F():F17-21. PubMed ID: 9447336 [TBL] [Abstract][Full Text] [Related]
32. Fibrinolytic agents: mechanisms of activity and pharmacology. Lijnen HR; Collen D Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491 [TBL] [Abstract][Full Text] [Related]
36. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Serebruany VL; Gurbel PA Thromb Haemost; 1999 Feb; 81(2):314-6. PubMed ID: 10064014 [No Abstract] [Full Text] [Related]
37. Procoagulant effects of thrombolytic therapy in acute myocardial infarction. Wang Y; Liu Q; Zhu J; Yuan Z; Ma X Chin Med Sci J; 2002 Mar; 17(1):36-9. PubMed ID: 12894883 [TBL] [Abstract][Full Text] [Related]
38. Biochemical and pharmacologic comparison of thrombolytic agents. Stringer KA Pharmacotherapy; 1996; 16(5 Pt 2):119S-126S. PubMed ID: 8888099 [TBL] [Abstract][Full Text] [Related]